Stock Events

Stock Events

Adagio Therapeutics 

$4.64
153
+$0.04+0.87%Monday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.2
-0.13
-0.07
-0
Expected EPS
-0.133333
Actual EPS
N/A

Financials

-7,448,500,000%Profit Margin
Unprofitable
2021
3Revenue
-223.46MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is ⁦10.00⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals competes in the development of monoclonal antibodies for the treatment of various diseases, similar to Invivyd's focus on antibody therapies.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is involved in the research and development of antiviral drugs, directly competing with Invivyd's efforts in infectious disease treatments.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca competes with Invivyd in the development of treatments for infections and diseases, including their work on vaccines and antibody therapies.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a direct competitor in the pharmaceutical and biotechnology industry, with a broad portfolio that includes treatments for infectious diseases, competing with Invivyd's focus.
Merck
MRK
Mkt Cap356.01B
Merck & Co. is involved in the creation of vaccines and therapeutic antibodies, competing with Invivyd in the infectious disease space.
Abbott Laboratories
ABT
Mkt Cap168.71B
Abbott Laboratories competes with Invivyd through its diagnostic and medical devices for infectious diseases, as well as its pharmaceutical products.
AMGEN
AMGN
Mkt Cap217.9B
Amgen focuses on human therapeutics, including treatments for infectious diseases, which puts it in competition with Invivyd's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb competes in the biopharmaceutical field, focusing on innovative medicines that include infectious disease treatments, similar to Invivyd's focus.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of drugs for infectious diseases, directly competing with Invivyd.
Sanofi
SNY
Mkt Cap95.65B
Sanofi competes with Invivyd in the global healthcare market, particularly in the development of vaccines and treatments for infectious diseases.

About

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Show More
CEO
Country
United States
ISIN
US00534A1025

Listings

XNAS
US
IVVD
BOATS
BOATS
IVVD.BOATS

0 Comments

Share your thoughts

FAQs

What is Adagio Therapeutics stock price today?▼
The current price of ADGI is $4.64 USD — it has increased by +0.87% in the past 24 hours. Watch Adagio Therapeutics stock price performance more closely on the chart.
What is Adagio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Adagio Therapeutics stocks are traded under the ticker ADGI.
What were Adagio Therapeutics earnings last quarter?▼
ADGI earnings for the last quarter are 0 USD per share, whereas the estimation was -0.46 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adagio Therapeutics revenue for the last year?▼
Adagio Therapeutics revenue for the last year amounts to 3 USD.
What is Adagio Therapeutics net income for the last year?▼
ADGI net income for the last year is -223.46M USD.
In which sector is Adagio Therapeutics located?▼
Adagio Therapeutics operates in the Other sector.
When did Adagio Therapeutics complete a stock split?▼
Adagio Therapeutics has not had any recent stock splits.